Carcinogenicity, Category 2
H351 Suspected of causing cancer
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P318 IF exposed or concerned, get medical advice.
P405 Store locked up.
P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
no data available
Move the victim into fresh air. If breathing is difficult, give oxygen. If not breathing, give artificial respiration and consult a doctor immediately. Do not use mouth to mouth resuscitation if the victim ingested or inhaled the chemical.
Take off contaminated clothing immediately. Wash off with soap and plenty of water. Consult a doctor.
Rinse with pure water for at least 15 minutes. Consult a doctor.
Rinse mouth with water. Do not induce vomiting. Never give anything by mouth to an unconscious person. Call a doctor or Poison Control Center immediately.
SYMPTOMS: Symptoms of exposure to this compound include sedation, nausea, drowsiness, ataxia and coma (from large doses). Other symptoms include vomiting, lethargy, hyporeflexia, muscular weakness, dysarthria, nystagmus, hypotension, respiratory failure and death from respiratory or cardiac arrest. Exposure can cause syncope, liver damage, bone marrow damage and sensitivity reactions. It can also cause dryness of the mouth, aggressive behavior, blood dyscrasias and hepatic dysfunction. Sleepiness has been reported. It may cause lightheadedness, respiratory depression, constipation, changes in salivation, blurred vision, diplopia, urinary retention, incontinence, mental depression, tremor, headache, confusion, slurred speech, vertigo, changes in libido, blood disorders, jaundice, central nervous system depression and, sometimes, paradoxical reactions such as dysphoria. It may also cause skin rashes (morbilliform, urticarial and maculopapular), dizziness, stimulation of affect, leukopenia, severe rage reactions (rare), menstrual irregularities, change in EEG pattern, agranulocytosis, stupor, disorientation, fever, euphoria, transient amnesia and memory impairment. Exposure to children has resulted in somnolence, changes in REM sleep and loss of muscle control (ataxia). It has also caused lethargy, paradoxical excitation, depressed reflexes, facial edema, delirium, hallucinations and convulsions. ACUTE/CHRONIC HAZARDS: When heated to decomposition this compound emits very toxic fumes of nitrogen oxides and hydrogen chloride. (NTP, 1992)
Treatment is entirely supportive with IV access and fluids and maintenance of the airway and ventilation if required. Patients with a significant sedative drug overdose should be advised not to drive until potential interference with psychomotor performance has resolved. For significant benzodiazepine overdose, this is at least 24 hours after discharge./Benzodiazepines/
Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
Flash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Wear self-contained breathing apparatus for firefighting if necessary.
Avoid dust formation. Avoid breathing mist, gas or vapours.Avoid contacting with skin and eye. Use personal protective equipment.Wear chemical impermeable gloves. Ensure adequate ventilation.Remove all sources of ignition. Evacuate personnel to safe areas.Keep people away from and upwind of spill/leak.
Prevent further spillage or leakage if it is safe to do so. Do not let the chemical enter drains. Discharge into the environment must be avoided.
Collect and arrange disposal. Keep the chemical in suitable and closed containers for disposal. Remove all sources of ignition. Use spark-proof tools and explosion-proof equipment. Adhered or collected material should be promptly disposed of, in accordance with appropriate laws and regulations.
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Oxazepam capsules and tablets should be stored in well-closed containers at a temperature less than 40 deg C, preferably at 15-30 deg C.
no data available
no data available
Ensure adequate ventilation. Handle in accordance with good industrial hygiene and safety practice. Set up emergency exits and the risk-elimination area.
Wear tightly fitting safety goggles with side-shields conforming to EN 166(EU) or NIOSH (US).
Wear fire/flame resistant and impervious clothing. Handle with gloves. Gloves must be inspected prior to use. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.
If the exposure limits are exceeded, irritation or other symptoms are experienced, use a full-face respirator.
no data available
PHYSICAL DESCRIPTION: Odorless creamy-white to pale-yellow powder or white crystalline solid. Bitter taste. pH (2% aqueous suspension) 4.8-7. (NTP, 1992)
Crystals from alcohol
PRACTICALLY ODORLESS
205-206°C
506.5°C at 760 mmHg
no data available
no data available
11°C
no data available
no data available
BETWEEN 4.8 AND 7.0 (1 IN 50 SUSPENSION)
no data available
less than 1 mg/mL at 66° F (NTP, 1992)
no data available
4.2X10-12 mm Hg at 25 deg C /Estimated/
1.42g/cm3
no data available
no data available
no data available
Stable in light
OXAZEPAM is stable in light and is non hygroscopic. It is stable in neutral solution. This chemical is hydrolyzed by acids and bases. (NTP, 1992)
no data available
no data available
no data available
no data available
no data available
no data available
no data available
Evaluation: There is inadequate evidence in humans for the carcinogenicity of oxazepam. There is sufficient evidence in experimental animals for the carcinogenicity of oxazepam. Overall Evaluation: Oxazepam is possibly carcinogenic to humans (Group 2B). In making the overall evaluation, the Working Group took into account that: (1) uncertainty exists regarding the formation of mouse liver tumors by oxazepam as a relevant end point for evaluation of carcinogenic risks to humans. (2) appropriate mechanistic information in humans is lacking.
no data available
no data available
no data available
no data available
no data available
An estimated BCF of 11 was calculated for oxazepam(SRC), using a log Kow of 2.24(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).
The Koc of oxazepam is estimated as 390(SRC), using a log Kow of 2.24(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that oxazepam is expected to have moderate mobility in soil.
no data available
The material can be disposed of by removal to a licensed chemical destruction plant or by controlled incineration with flue gas scrubbing. Do not contaminate water, foodstuffs, feed or seed by storage or disposal. Do not discharge to sewer systems.
Containers can be triply rinsed (or equivalent) and offered for recycling or reconditioning. Alternatively, the packaging can be punctured to make it unusable for other purposes and then be disposed of in a sanitary landfill. Controlled incineration with flue gas scrubbing is possible for combustible packaging materials.
ADR/RID: UN1230 (For reference only, please check.)
IMDG: UN1230 (For reference only, please check.)
IATA: UN1230 (For reference only, please check.)
ADR/RID: METHANOL (For reference only, please check.)
IMDG: METHANOL (For reference only, please check.)
IATA: METHANOL (For reference only, please check.)
ADR/RID: 3 (For reference only, please check.)
IMDG: 3 (For reference only, please check.)
IATA: 3 (For reference only, please check.)
ADR/RID: II (For reference only, please check.)
IMDG: II (For reference only, please check.)
IATA: II (For reference only, please check.)
ADR/RID: No
IMDG: No
IATA: No
no data available
no data available